Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis Meeting Abstract
| Authors: | McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; Gurney, H. P.; Grimm, M. O.; Harrison, M.; Hutson, T. E.; Doan, J.; Yang, S.; Rao, S.; Mekan, S.; Ambavane, A.; Powles, T. |
| Abstract Title: | Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy283.083 |
| Language: | English |
| ACCESSION: | WOS:000459277302057 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy283.083 |
| Notes: | Meeting Abstract: 874P -- Appears on page viii309 of the abstract book -- Source: Wos |
